5-Hydroxytryptophan during critical postnatal period improves cognitive performances and promotes dendritic spine maturation in genetic mouse model of phenylketonuria.
Although phenylketonuria (PKU) is the most common genetic cause of mental retardation, the cellular mechanisms underlying impaired brain function are still unclear. Using PAHenu2 mice (ENU2), the genetic mouse model of PKU, we previously demonstrated that high phenylalanine levels interfere with brain tryptophan hydroxylase activity by reducing the availability of serotonin (5-hydroxytryptamine, 5-HT), crucial for maturation of neuronal connectivity in the prefrontal cortex (PFC), around the third postnatal week, a critical period for cortical maturation. 5-Hydroxytryptophan (5-HTP), the product of tryptophan hydroxylation, is known to be a better treatment to increase brain 5-HT levels. In this study we investigated the role of 5-HT during the early postnatal period in cognitive disturbances and in cortical dendritic alterations of PKU subjects by restoring temporarily (postnatal days 14-21) physiological brain levels of 5-HT in ENU2 through 5-HTP treatment. In adult ENU2 mice early 5-HTP treatment reverses cognitive deficits in spatial and object recognition tests accompanied by an increase in spine maturation of pyramidal neurons in layer V of the prelimbic/infralimbic area of the PFC, although locomotor deficits are not recovered by treatment. Taken together, our results support the hypothesis that mental retardation in PKU depends on reduced availability of brain 5-HT during critical developmental periods that interferes with cortical maturation and point to 5-HTP supplementation as a highly promising additional tool to heal PKU patients.
Dipartimento di Psicologia and Centro 'Daniel Bovet', 'Sapienza' University, Rome, Italy.
Diego
D
Andolina
David
D
Conversi
Simona
S
Cabib
Antonio
A
Trabalza
Rossella
R
Ventura
Stefano
S
Puglisi-Allegra
Tiziana
T
Pascucci
D006916:5-Hydroxytryptophan / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003071:Cognition; D003072:Cognition Disorders / Q000150:complications / Q000235:genetics / Q000503:physiopathology; D003423:Critical Period, Psychological; D049229:Dendritic Spines / Q000187:drug effects* / Q000502:physiology; D004195:Disease Models, Animal; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D010651:Phenylalanine Hydroxylase / Q000378:metabolism; D010661:Phenylketonurias / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000503:physiopathology; D012701:Serotonin / Q000378:metabolism*; D013997:Time Factors
D012701:Serotonin; D006916:5-Hydroxytryptophan; D010651:Phenylalanine Hydroxylase